Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
- 7 October 2004
- journal article
- fast track
- Published by Wiley in International Journal of Cancer
- Vol. 113 (4), 525-532
- https://doi.org/10.1002/ijc.20631
Abstract
A prominent phenotype of plasmin deficiency in mice is reduced metastasis in the MMTV-PymT transgenic breast cancer model. Proteolytically active plasmin is generated from inactive plasminogen by one of 2 activators, uPA or tPA. We now find that uPA deficiency alone significantly reduces metastasis >7-fold in the MMTV-PymT model. We studied a cohort of 55 MMTV-PymT transgenic mice, either uPA-deficient or wild-type controls. Tumor incidence, latency, growth rate and final primary tumor burden were not significantly affected by uPA deficiency. In contrast, average lung metastasis volume was reduced from 1.58 mm(3) in wild-type controls to 0.21 mm(3) in uPA-deficient mice (p = 0.023). Tumor cell dissemination to brachial lymph nodes was also reduced from 53% (28/53) in wild-type controls to 31% (17/54) in uPA-deficient mice (p = 0.032). Mice without plasminogen display a severe pleiotropic phenotype. By comparison, spontaneous phenotypes are modest in uPA-deficient mice, probably because they still have active tPA. We show that metastasis is strongly and selectively decreased in uPA-deficient mice, suggesting that uPA-directed antimetastatic therapy would be efficacious and have limited side effects.Funding Information
- Astrid Thaysen's Foundation
- Weimann's Foundation
- Danish Cancer Research Foundation
- Danish Cancer Society
- European Commission (QLG1-CT-2000-01131, LSHC-CT-2003-503297)
- Danish Research Agency
- Copenhagen Hospital Corporation
This publication has 48 references indexed in Scilit:
- Human and mouse proteases: a comparative genomic approachNature Reviews Genetics, 2003
- Cellular mechanisms regulating non-haemostatic plasmin generationBiochemical Society Transactions, 2002
- A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiationNature, 2001
- The plasminogen activation system in tumor growth, invasion, and metastasisCellular and Molecular Life Sciences, 2000
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic GlomerulonephritisThe Journal of Experimental Medicine, 1997
- Plasminogen Activation on Tumor Cell Surface and its Involvement in Human LeukemiaAdvances in Cancer Research, 1996
- Physiological consequences of loss of plasminogen activator gene function in miceNature, 1994
- Biological Effects of Disruption of the Tissue‐Type Plasminogen Activator, Urokinase‐Type Plasminogen Activator, and Plasminogen Activator Inhibitor‐1 Genes in MiceaAnnals of the New York Academy of Sciences, 1994
- Plasminogen Activation Initiated by Single-chain Urokinase-type Plasminogen ActivatorOnline Journal of Public Health Informatics, 1989